COVID-19, like other infectious diseases, may be a risk factor for psychotic disorders. We aimed to compare the proportions of hospitalizations for psychotic disorders in the 12 months following discharge from hospital for either COVID-19 or for another reason in the adult general population in France during the first wave of the pandemic. We conducted a retrospective longitudinal nationwide study using the national French administrative healthcare database. Psychotic disorders were first studied as a whole, and then chronic and acute disorders separately. The role of several adjustment factors, including sociodemographics, a history of psychotic disorder, the duration of the initial hospitalization, and the level of care received during that hospitalization, were also analyzed. Between 1 January 2020 and 30 June 2020, a total of 14,622 patients were hospitalized for psychotic disorders in the 12 months following discharge from hospital for either COVID-19 or another reason. Initial hospitalization for COVID-19 (vs. another reason) was associated with a lower rate of subsequent hospitalization for psychotic disorders (0.31% vs. 0.51%, odds ratio (OR) = 0.60, 95% confidence interval (CI) [0.53-0.67]). This was true for both chronic and acute disorders, even after adjusting for the various study variables. Importantly, a history of psychotic disorder was a major determinant of hospitalization for psychotic disorders (adjusted OR = 126.56, 95% CI [121.85-131.46]). Our results suggest that, in comparison to individuals initially hospitalized for another reason, individuals initially hospitalized for COVID-19 present a lower risk of hospitalization for first episodes of psychotic symptoms/disorders or for psychotic relapse in the 12 months following discharge. This finding contradicts the hypothesis that there is a higher risk of psychotic disorders after a severe COVID-19.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
The SNDS (National French administrative healthcare database) comprises a set of strictly pseudonymized databases. By law, Santé Publique France, the French agency for public health, has permanent regulatory access to SNDS data for the performance of its missions (article L.1461-3 and R1461-13 and following of the French public health code ). Access to personal data in these systems for research purposes is subject to obtaining authorization from the CNIL (National Commission on Information Technology and Civil Liberties), after approval from the Comité éthique et scientifique pour les recherches, les études et les évaluations dans le domaine de la santé (CESREES, Ethics and Scientific Committee for Research, Studies and Evaluation in the field of health).
Xiang Y-T, Yang Y, Li W, Zhang L, Zhang Q, Cheung T, et al. Timely mental health care for the 2019 novel coronavirus outbreak is urgently needed. Lancet Psychiatry. 2020;7:228–9.
Holmes EA, O’Connor RC, Perry VH, Tracey I, Wessely S, Arseneault L, et al. Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. Lancet Psychiatry. 2020;7:547–60.
Benros ME, Nielsen PR, Nordentoft M, Eaton WW, Dalton SO, Mortensen PB. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am J Psychiatry. 2011;168:1303–10.
Khandaker GM, Zimbron J, Dalman C, Lewis G, Jones PB. Childhood infection and adult schizophrenia: A meta-analysis of population-based studies. Schizophrenia Res. 2012;139:161–8.
Nielsen PR, Benros ME, Mortensen PB. Hospital contacts with infection and risk of schizophrenia: a population-based cohort study with linkage of danish national registers. Schizophrenia Bull. 2014;40:1526–32.
Leboyer M, Berk M, Yolken RH, Tamouza R, Kupfer D, Groc L. Immuno-psychiatry: an agenda for clinical practice and innovative research. BMC Med. 2016;14:173.
De Picker LJ, Morrens M, Chance SA, Boche D. Microglia and brain plasticity in acute psychosis and schizophrenia illness course: a meta-review. Front Psychiatry. 2017;8:238.
Pape K, Tamouza R, Leboyer M, Zipp F. Immunoneuropsychiatry - novel perspectives on brain disorders. Nat Rev Neurol. 2019;15:317–28.
Ferrando SJ, Klepacz L, Lynch S, Tavakkoli M, Dornbush R, Baharani R, et al. COVID-19 psychosis: a potential new neuropsychiatric condition triggered by novel coronavirus infection and the inflammatory response? Psychosomatics 2020;61:551–5.
Beards S, Gayer-Anderson C, Borges S, Dewey ME, Fisher HL, Morgan C. Life events and psychosis: a review and meta-analysis. Schizophr Bull. 2013;39:740–7.
Pignon B, Lajnef M, Kirkbride JB, Peyre H, Ferchiou A, Richard J-R, et al. The independent effects of psychosocial stressors on subclinical psychosis: findings from the multinational EU-GEI study. Schizophrenia Bull. 2021;47:1674–84.
Pignon B, Peyre H, Ayrolles A, Kirkbride JB, Jamain S, Ferchiou A, et al. Genetic and psychosocial stressors have independent effects on the level of subclinical psychosis: findings from the multinational EU-GEI study. Epidemiol Psychiatr Sci. 2022;31:e68.
Fond G, Pauly V, Leone M, Llorca P-M, Orleans V, Loundou A, et al. Disparities in intensive care unit admission and mortality among patients with schizophrenia and COVID-19: A national cohort study. Schizophrenia Bull. 2021;47:624–34.
Fond G, Nemani K, Etchecopar-Etchart D, Loundou A, Goff DC, Lee SW, et al. Association between mental health disorders and mortality among patients with COVID-19 in 7 countries: a systematic review and meta-analysis. JAMA Psychiatry. 2021;78:1208–17.
Vai B, Mazza MG, Delli Colli C, Foiselle M, Allen B, Benedetti F, et al. Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis. Lancet Psychiatry. 2021;8:797–812.
Lynch A, Bastiampillai T, Dhillon R. Can COVID-19-related anxiety trigger a relapse of schizophrenia? Aust N Z J Psychiatry. 2021;55:732–732.
Lim MH, Gleeson JFM, Alvarez-Jimenez M, Penn DL. Loneliness in psychosis: a systematic review. Soc Psychiatry Psychiatr Epidemiol. 2018;53:221–38.
Ma J, Hua T, Zeng K, Zhong B, Wang G, Liu X. Influence of social isolation caused by coronavirus disease 2019 (COVID-19) on the psychological characteristics of hospitalized schizophrenia patients: a case-control study. Transl Psychiatry. 2020;10:1–5.
Busch AB, Huskamp HA, Raja P, Rose S, Mehrotra A. Disruptions in care for medicare beneficiaries with severe mental illness during the COVID-19 pandemic. JAMA Netw Open. 2022;5:e2145677.
van den Borst B, Peters JB, Brink M, Schoon Y, Bleeker-Rovers CP, Schers H, et al. Comprehensive health assessment 3 months after recovery from acute coronavirus disease 2019 (COVID-19). Clin Infect Dis. 2021;73:e1089–e1098.
Bo H-X, Li W, Yang Y, Wang Y, Zhang Q, Cheung T, et al. Posttraumatic stress symptoms and attitude toward crisis mental health services among clinically stable patients with COVID-19 in China. Psychol Med. 2021;51:1052–3.
Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021;397:220–32.
Veazie S, Lafavor B, Vela K, Young S, Sayer NA, Carlson KF, et al. Mental health outcomes of adults hospitalized for COVID-19: A systematic review. J Affect Disord Rep. 2022;8:100312.
Huarcaya-Victoria J, Herrera D, Castillo C. Psychosis in a patient with anxiety related to COVID-19: A case report. Psychiatry Res. 2020;289:113052.
Parra A, Juanes A, Losada CP, Álvarez-Sesmero S, Santana VD, Martí I, et al. Psychotic symptoms in COVID-19 patients. A retrospective descriptive study. Psychiatry Res. 2020;291:113254.
Santos NF, Alho AP, Costa ID, Ferreira LP, Sêco EH. First-episode psychosis with delusional jealousy during SARS-CoV-2 infection: COVID-19 secondary psychosis or a trigger for a primary psychotic disorder? Prim Care Companion CNS Disord. 2021;23:37203.
Chaudhary AMD, Musavi NB, Saboor S, Javed S, Khan S, Naveed S. Psychosis during the COVID-19 pandemic: A systematic review of case reports and case series. J Psychiatr Res. 2022;153:37–55.
Xiao Y, Sharma MM, Thiruvalluru RK, Gimbrone C, Weissman MM, Olfson M, et al. Trends in psychiatric diagnoses by COVID-19 infection and hospitalization among patients with and without recent clinical psychiatric diagnoses in New York city from March 2020 to August 2021. Transl Psychiatry. 2022;12:492.
Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8:416–27.
Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2021;8:130–40.
Taquet M, Sillett R, Zhu L, Mendel J, Camplisson I, Dercon Q, et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatry. 2022;9:815–27.
Clift AK, Ranger TA, Patone M, Coupland CAC, Hatch R, Thomas K, et al. Neuropsychiatric ramifications of severe COVID-19 and other severe acute respiratory infections. JAMA Psychiatry. 2022;79:690–8.
Decio V, Pirard P, Pignon B, Bouaziz O, Perduca V, Chin F, et al. Hospitalization for COVID-19 is associated with a higher risk of subsequent hospitalization for psychiatric disorders: a French nationwide longitudinal study comparing hospitalizations for COVID-19 and for other reasons. Eur Psychy. 2022:1–13.
Caisse Nationale d’Assurance Maladie (CNAM). https://www.ameli.fr/sites/default/files/2020_methode-reperage-pathologies_cartographie.pdf. 2020.
Rachas A, Gastaldi-Ménager C, Denis P, Barthélémy P, Constantinou P, Drouin J, et al. The economic burden of disease in france from the national health insurance perspective. Med Care. 2022;60:655–64.
Rey G, Rican S, Jougla E. Mesure des inégalités de mortalité par cause de décès. Approche écologique à l’aide d’un indice de désavantage social. Bull Epidémiologique Hebd. 2011;8–9:87–90.
Code de la santé publique. Chapitre Ier: Système national des données de santé (Articles R1461-1 à R1461-17). 2019. https://www.legifrance.gouv.fr/codes/section_lc/LEGITEXT000006072665/LEGISCTA000033707685/#LEGISCTA000033708020.
Szöke A, Baudin G, Saba G, Pignon B, Richard J-R, Leboyer M, et al. Prevalence of psychotic disorders in an urban area of France. BMC Psychiatry. 2015;15:204.
Szöke A, Charpeaud T, Galliot A-M, Vilain J, Richard J-R, Leboyer M, et al. Rural-urban variation in incidence of psychosis in France: a prospective epidemiologic study in two contrasted catchment areas. BMC Psychiatry. 2014;14:78.
O’Donoghue B, Collett H, Boyd S, Zhou Y, Castagnini E, Brown E, et al. The incidence and admission rate for first-episode psychosis in young people before and during the COVID-19 pandemic in Melbourne, Australia. Aust N Z J Psychiatry. 2022;56:811–7.
Davydow DS, Hough CL, Zatzick D, Katon WJ. Psychiatric symptoms and acute care service utilization over the course of the year following medical-surgical ICU admission: a longitudinal investigation*. Crit Care Med. 2014;42:2473–81.
Leung JYT, Barr AM, Procyshyn RM, Honer WG, Pang CCY. Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system. Pharm Ther. 2012;135:113–22.
Barbui C, Conti V, Cipriani A. Antipsychotic drug exposure and risk of venous thromboembolism: a systematic review and meta-analysis of observational studies. Drug Saf. 2014;37:79–90.
Lücke C, Gschossmann JM, Grömer TW, Moeller S, Schneider CE, Zikidi A, et al. Off-label prescription of psychiatric drugs by non-psychiatrist physicians in three general hospitals in Germany. Ann Gen Psychiatry. 2018;17:7.
Bowtell M, Eaton S, Thien K, Bardell-Williams M, Downey L, Ratheesh A, et al. Rates and predictors of relapse following discontinuation of antipsychotic medication after a first episode of psychosis. Schizophrenia Res. 2018;195:231–6.
Crump C, Winkleby MA, Sundquist K, Sundquist J. Comorbidities and mortality in persons with schizophrenia: a swedish national cohort study. AJP. 2013;170:324–33.
Fan Z, Wu Y, Shen J, Ji T, Zhan R. Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies. J Psychiatr Res. 2013;47:1549–56.
Hayes JF, Marston L, Walters K, King MB, Osborn DPJ. Mortality gap for people with bipolar disorder and schizophrenia: UK-based cohort study 2000–2014. Br J Psychiatry. 2017;211:175–81.
Kowal C, Peyre H, Amad A, Pelissolo A, Leboyer M, Schürhoff F, et al. Psychotic, mood, and anxiety disorders and venous thromboembolism: a systematic review and meta-analysis. Psychosom Med. 2020;82:838–49.
Chevance A, Gourion D, Hoertel N, Llorca P-M, Thomas P, Bocher R, et al. Ensuring mental health care during the SARS-CoV-2 epidemic in France: A narrative review. Encephale. 2020. 2020. https://doi.org/10.1016/j.encep.2020.03.001.
Pignon B, Gourevitch R, Tebeka S, Dubertret C, Cardot H, Dauriac-Le Masson V, et al. Dramatic reduction of psychiatric emergency consultations during lockdown linked to COVID-19 in Paris and suburbs. Psychiatry Clin Neurosci. 2020;74:557–9.
Mariet A-S, Giroud M, Benzenine E, Cottenet J, Roussot A, Aho-Glélé LS, et al. Hospitalizations for stroke in france during the COVID-19 pandemic before, during, and after the national lockdown. Stroke 2021;52:1362–9.
Mariet A-S, Benzenine E, Bouillet B, Vergès B, Quantin C, Petit J-M. Impact of the COVID-19 epidemic on hospitalization for diabetic foot ulcers during lockdown: A French nationwide population-based study. Diabet Med. 2021;38:e14577.
Olié E, Nogue E, Picot M, Courtet P. Hospitalizations for suicide attempt during the first COVID‐19 lockdown in France. Acta Psychiatr Scand. 2021;143:535–6.
Abel KM, Drake R, Goldstein JM. Sex differences in schizophrenia. Int Rev Psychiatry. 2010;22:417–28.
Chi MH, Hsiao CY, Chen KC, Lee L-T, Tsai HC, Hui Lee I, et al. The readmission rate and medical cost of patients with schizophrenia after first hospitalization — A 10-year follow-up population-based study. Schizophrenia Res. 2016;170:184–90.
Immonen J, Jääskeläinen E, Korpela H, Miettunen J. Age at onset and the outcomes of schizophrenia: A systematic review and meta-analysis. Early Intervention Psychiatry. 2017;11:453–60.
Boyer L, Fond G, Pauly V, Orléans V, Auquier P, Solmi M, et al. Impact of the COVID-19 pandemic on non-COVID-19 hospital mortality in patients with schizophrenia: a nationwide population-based cohort study. Mol Psychiatry. 2022;27:5186–94.
Font H, Roelandt J-L, Behal H, Geoffroy P-A, Pignon B, Amad A, et al. Prevalence and predictors of no lifetime utilization of mental health treatment among people with mental disorders in France: findings from the ‘Mental Health in General Population’ (MHGP) survey. Soc Psychiatry Psychiatr Epidemiol. 2018;53:567–76.
We thank Guillaume Airagnes, Christine Chan Chee, Mounia El Yamani, Anne Gallay, Catherine Ha, Mathilde Horn, Maria Melchior and Claudie Menguy, whose insight and expertize enhanced the quality of this study. We are also very grateful to Jude Sweeney for copyediting comments which greatly improved the manuscript. Cédric Lemogne and Baptiste Pignon were supported by a grant “AAP Covid long 2022-1” from the Agence nationale de recherches sur le sida et les hépatites virales (ANRS) | Maladies infectieuses émergentes.
Prof. Lemogne reports non-financial support from Nordic Pharma France, outside the submitted work. Prof. Messika received congress reimbursement fees from Biotest and CSL Behring. The other authors have no conflicts of interest to declare.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Table 2. Comparison of patients previously hospitalized for COVID-19 and those previously hospitalized for another reason among persons subsequently hospitalized for any psychotic disord
Supplementary Table 3. Rates of hospitalization with (i.e., principal or associated diagnosis) or for (i.e., principal diagnosis only) a psychotic disorder after previous hospitalization for COVID-19
Supplementary Table 4. Rates of hospitalization with a diagnosis a psychotic disorder (i.e., principal or associated diagnosis) in psychiatric ward after previous hospitalization for COVID-19 or for a
Supplementary Table 5. Association of previous COVID-19 hospitalization with subsequent (12-month) hospitalization with a diagnosis of a psychotic disorder (i.e., principal or associated diagnosis) am
Supplementary Table 6. Association of previous COVID-19 hospitalization with subsequent (12-month) hospitalization with a diagnosis of an acute psychotic disorder (i.e., principal or associated diagno
About this article
Cite this article
Pignon, B., Decio, V., Pirard, P. et al. The risk of hospitalization for psychotic disorders following hospitalization for COVID-19: a French nationwide longitudinal study. Mol Psychiatry 28, 3293–3304 (2023). https://doi.org/10.1038/s41380-023-02207-8